GW Pharmaceuticals shares attractive ahead of data, says Leerink After meeting with management, Leerink says is continue to view shares of GW Pharmaceuticals as attractive here ahead of additional Epidiolex data readouts and the commencement of pivotal trials in the second half of 2014. The firm reiterates an Outperform rating on the stock with a $110 price target.
News For GWPH From The Last 14 Days
Check below for free stories on GWPH the last two weeks.
GW Pharmaceuticals could trade up 25% on data, says Leerink Leerink believes shares of GW Pharmaceuticals could trade up 25% should the Epidiolex data in pediatric epilepsy show a seizure reduction materially greater than 44%. The data is expected in the second half of 2014. The firm says shares could trade up 15% higher on a reduction at or close to 40%, or 15% lower if the mean reduction is in the 20%-30% range. Leerink is bullish ahead of the data readout after reviewing the cannabidiol epilepsy literature and previous anti-epileptic drug trials. It has an Outperform rating on shares of GW Pharmaceuticals with a $110 price target.